Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
BUPIVACAINE HYDROCHLORIDE
BAXTER CORPORATION
N01BB01
BUPIVACAINE
2.5MG
SOLUTION
BUPIVACAINE HYDROCHLORIDE 2.5MG
BLOCK/INFILTRATION
100
Ethical
LOCAL ANESTHETICS
Active ingredient group (AIG) number: 0108896001; AHFS:
APPROVED
2019-05-23
_ _ _Bupivacaine Hydrochloride Injection, USP Product Monograph Page 1 of 35_ PRODUCT MONOGRAPH BUPIVACAINE HYDROCHLORIDE INJECTION, USP 2.5 mg/mL, 5 mg /mL and 7.5 mg/mL Bupivacaine Hydrochloride, USP Sterile Solution Local Anesthetic BAXTER CORPORATION Mississauga, Ontario L5N 0C2 Date of Preparation: May 22, 2019 Submission Control No: 210568 _ _ _Bupivacaine Hydrochloride Injection, USP Product Monograph Page 2 of 35_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 13 DOSAGE AND ADMINISTRATION ............................................................................. 14 OVERDOSAGE ............................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 21 STORAGE AND STABILITY ......................................................................................... 23 SPECIAL HANDLING INSTRUCTIONS ...................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 24 PART II: SCIENTIFIC INFORMATION .............................................................................. 26 PHARMACEUTICAL INFORMATION .................................................. Přečtěte si celý dokument